Published in:
Open Access
01-12-2019 | Coronary Heart Disease | Research article
Past history of stage I/II solid tumor malignancy impacts considerably on sepsis mortality: a propensity score matching analysis from the hellenic sepsis study group
Authors:
George Dimοpoulos, Nikoletta Rovina, Maria Patrani, Eleni Antoniadou, Dimitrios Konstantonis, Konstantina Vryza, Glykeria Vlachogianni, Miltiades Kyprianou, Christina Routsi, Evangelos J. Giamarellos-Bourboulis, on behalf of the Hellenic Sepsis Study Group
Published in:
BMC Infectious Diseases
|
Issue 1/2019
Login to get access
Abstract
Background
Whether past history of solid stage I/II inactive cancer has an impact on 28-day mortality of sepsis remains unclear. We aimed to determine the impact of history of stage I or II solid tumor malignancy in complete remission the last 3 years on sepsis outcome.
Methods
Using the database of the Hellenic Sepsis Study Group from 1553 patients with sepsis admitted in the ICU, 83 patients with sepsis by Sepsis-3 definition with past-history of stage I/II inactive solid malignancy the last 3 years were depicted. A comparator group of 83 patients fully matched for age, severity, type of infection and comorbidities was selected by propensity score matching.
Results
Mortality after 28 days was 37.3% in the comparator group and 54.2% in the solid tumor stage I/II group (odds ratio for death 1.98; p: 0.030). Following step-wise forward Cox regression analysis, septic shock (hazard ratio 1.80), acute renal injury (hazard ratio 2.06), history of coronary heart disease (hazard ratio 0.36) and history of stage I/II solid tumor malignancy (hazard ratio 1.79) were the only independent variables associated with 28-day mortality. Serum levels of procalcitonin and of soluble urokinase plasminogen activator receptor were similar between the two groups of comparisons.
Conclusions
Past history of stage I/II solid malignancy is an independent risk factor for unfavorable outcome from sepsis the first 28 days.